Flöter Rådestad A

No ORCID on file · 1 paper in corpus

2026

Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers.

Communications medicine ·doi:10.1038/s43856-026-01412-0

BackgroundProgesterone receptor antagonists such as mifepristone have emerged as candidates for breast cancer prevention, particularly in high-risk populations such as BRCA1/2 pathogenic variant carriers. However, their impact on endometria…